NMPA accepts clinical trial application for monkeypox vaccine
chinadaily.com.cn |
Updated: 2023-07-14 19:44
Share
Share - WeChat
The National Medical Products Administration (NMPA) has, on Thursday, officially accepted the clinical trial application for the replication-deficient monkeypox vaccine developed by China National Pharmaceutical Group Corporation (Sinopharm) Beijing Institute of Biological Products.
- Viral video shows meteor streaking over Helan Mountains in Ningxia
- China innovates network technology, achieving efficient data transmission
- More international maritime disputes turn to China's courts
- Chinese researchers inject AI power to evidence-based medicine
- Harbin Ice and Snow World opens with expanded park
- Visa-free transit policies spur surge of foreign visitors
